scholarly article | Q13442814 |
P356 | DOI | 10.1586/14787210.4.6.917 |
P8608 | Fatcat ID | release_nkyy4drkfbczvp6ecrtsspcrza |
P698 | PubMed publication ID | 17181407 |
P5875 | ResearchGate publication ID | 6619676 |
P2093 | author name string | Mike Bray | |
Richard Pilch | |||
P2860 | cites work | Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions | Q35895035 |
Filovirus assembly and budding | Q36346797 | ||
Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody | Q39683688 | ||
Functional characterization of Ebola virus L-domains using VSV recombinants | Q40422906 | ||
Epitopes involved in antibody-mediated protection from Ebola virus | Q40625468 | ||
Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections | Q44089771 | ||
Ebola hemorrhagic fever and septic shock | Q44090615 | ||
Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement | Q49168123 | ||
Multiple Ebola Virus Transmission Events and Rapid Decline of Central African Wildlife | Q22299362 | ||
Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. | Q25256700 | ||
Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty | Q28196508 | ||
Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection | Q28588877 | ||
Ebola virus VP40 late domains are not essential for viral replication in cell culture | Q33911884 | ||
Experimental therapy of filovirus infections | Q33957838 | ||
Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event | Q33974171 | ||
Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys | Q33974706 | ||
Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses | Q34317031 | ||
Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment | Q34519791 | ||
Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference | Q34526756 | ||
Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever | Q34557675 | ||
Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling | Q34648134 | ||
Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation | Q34648461 | ||
Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis | Q35128436 | ||
Activated protein C in sepsis: emerging insights regarding its mechanism of action and clinical effectiveness | Q35786305 | ||
Pathogenesis of filoviral haemorrhagic fevers | Q35853406 | ||
P433 | issue | 6 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 917-921 | |
P577 | publication date | 2006-12-01 | |
P1433 | published in | Expert Review of Anti-infective Therapy | Q15734432 |
P1476 | title | Filoviruses: recent advances and future challenges | |
P478 | volume | 4 |
Q38264960 | Clinical presentation and management of severe Ebola virus disease |
Q34536774 | Induction of caspase activation and cleavage of the viral nucleocapsid protein in different cell types during Crimean-Congo hemorrhagic fever virus infection |
Q37332576 | Interferon and cytokine responses to Crimean Congo hemorrhagic fever virus; an emerging and neglected viral zonoosis |
Q30205763 | Recent advances in research on Crimean-Congo hemorrhagic fever |
Search more.